121 related articles for article (PubMed ID: 22185962)
1. The effects of mycophenolate mofetil on encapsulated peritoneal sclerosis model in rats.
Hur E; Bozkurt D; Timur O; Bicak S; Sarsik B; Akcicek F; Duman S
Clin Nephrol; 2012 Jan; 77(1):1-7. PubMed ID: 22185962
[TBL] [Abstract][Full Text] [Related]
2. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model.
Ertilav M; Hur E; Bozkurt D; Sipahi S; Timur O; Sarsik B; Akcicek F; Duman S
Nephrology (Carlton); 2011 Aug; 16(6):552-7. PubMed ID: 21382127
[TBL] [Abstract][Full Text] [Related]
3. The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis.
Huddam B; Başaran M; Koçak G; Azak A; Yalçın F; Reyhan NH; Duranay M
Int Urol Nephrol; 2015 Aug; 47(8):1423-8. PubMed ID: 26159779
[TBL] [Abstract][Full Text] [Related]
4. A novel angiogenesis inhibitor, sunitinib malate, in encapsulating peritoneal sclerosis.
Bozkurt D; Sarsik B; Hur E; Ertilav M; Karaca B; Timur O; Bicak S; Akcicek F; Duman S
J Nephrol; 2011; 24(3):359-65. PubMed ID: 21240876
[TBL] [Abstract][Full Text] [Related]
5. The effects of colchicine on the progression and regression of encapsulating peritoneal sclerosis.
Bozkurt D; Bicak S; Sipahi S; Taskin H; Hur E; Ertilav M; Sen S; Duman S
Perit Dial Int; 2008 Nov; 28 Suppl 5():S53-7. PubMed ID: 19008543
[TBL] [Abstract][Full Text] [Related]
6. TGF-β1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis.
Kariya T; Nishimura H; Mizuno M; Suzuki Y; Matsukawa Y; Sakata F; Maruyama S; Takei Y; Ito Y
Am J Physiol Renal Physiol; 2018 Feb; 314(2):F167-F180. PubMed ID: 28978530
[TBL] [Abstract][Full Text] [Related]
7. Role of tyrosine kinase inhibition with imatinib in an encapsulating peritoneal sclerosis rat model.
Velioglu A; Tugtepe H; Asicioglu E; Yilmaz N; Filinte D; Arikan H; Koc M; Tuglular S; Kaya H; Ozener C
Ren Fail; 2013; 35(4):531-7. PubMed ID: 23473055
[TBL] [Abstract][Full Text] [Related]
8. Can N-acetylcysteine preserve peritoneal function and morphology in encapsulating peritoneal sclerosis?
Bozkurt D; Hur E; Ulkuden B; Sezak M; Nar H; Purclutepe O; Sen S; Duman S
Perit Dial Int; 2009 Feb; 29 Suppl 2():S202-5. PubMed ID: 19270218
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
Bozkurt D; Taskin H; Sezak M; Biçak S; Sen S; Ok E; Duman S
Adv Perit Dial; 2008; 24():32-8. PubMed ID: 18985998
[TBL] [Abstract][Full Text] [Related]
10. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model.
Duman S; Bozkurt D; Sipahi S; Sezak M; Ozkan S; Ertilav M; Sen S; Ok E
Adv Perit Dial; 2008; 24():104-10. PubMed ID: 18986012
[TBL] [Abstract][Full Text] [Related]
11. Pyrrole-imidazole polyamide targeting transforming growth factor β1 ameliorates encapsulating peritoneal sclerosis.
Serie K; Fukuda N; Nakai S; Matsuda H; Maruyama T; Murayama Y; Omata S
Perit Dial Int; 2012; 32(4):462-72. PubMed ID: 22215658
[TBL] [Abstract][Full Text] [Related]
12. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models.
Io H; Hamada C; Ro Y; Ito Y; Hirahara I; Tomino Y
Kidney Int; 2004 May; 65(5):1927-36. PubMed ID: 15086936
[TBL] [Abstract][Full Text] [Related]
13. Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis?
Bozkurt D; Sipahi S; Cetin P; Hur E; Ozdemir O; Ertilav M; Sen S; Duman S
Perit Dial Int; 2009 Feb; 29 Suppl 2():S206-10. PubMed ID: 19270219
[TBL] [Abstract][Full Text] [Related]
14. The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis.
Bozkurt D; Cetin P; Sipahi S; Hur E; Nar H; Ertilav M; Sezak M; Duman S
Perit Dial Int; 2008 Nov; 28 Suppl 5():S38-42. PubMed ID: 19008539
[TBL] [Abstract][Full Text] [Related]
15. Calcitriol decreases TGF-β1 and angiotensin II production and protects against chlorhexide digluconate-induced liver peritoneal fibrosis in rats.
Lee CJ; Subeq YM; Lee RP; Liou HH; Hsu BG
Cytokine; 2014 Jan; 65(1):105-18. PubMed ID: 24210651
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Rho-kinase alleviates peritoneal fibrosis and angiogenesis in a rat model of peritoneal dialysis.
Peng W; Zhou Q; Ao X; Tang R; Xiao Z
Ren Fail; 2013 Aug; 35(7):958-66. PubMed ID: 23859538
[TBL] [Abstract][Full Text] [Related]
17. Patients with encapsulating peritoneal sclerosis have increased peritoneal expression of connective tissue growth factor (CCN2), transforming growth factor-β1, and vascular endothelial growth factor.
Abrahams AC; Habib SM; Dendooven A; Riser BL; van der Veer JW; Toorop RJ; Betjes MG; Verhaar MC; Watson CJ; Nguyen TQ; Boer WH
PLoS One; 2014; 9(11):e112050. PubMed ID: 25384022
[TBL] [Abstract][Full Text] [Related]
18. The effects of low-dose erythropoiesis-stimulating agents on peritoneal fibrosis induced by chemical peritonitis and on peritoneal tissue MMP-2 and TIMP-2 Levels in rats.
Yildirim A; Ozkan OV; Aslan A; Koseoglu Z; Borazan A
Ren Fail; 2009; 31(7):567-72. PubMed ID: 19839852
[TBL] [Abstract][Full Text] [Related]
19. Abatacept as a therapeutic option in the treatment of encapsulated peritoneal sclerosis: an experimental rat model.
Bircan L; Karakose S; Unverdi H; Bal AZ; Unverdi S; Duranay M
Int Urol Nephrol; 2017 May; 49(5):909-916. PubMed ID: 28190234
[TBL] [Abstract][Full Text] [Related]
20. Tanshinone IIA attenuates peritoneal fibrosis through inhibition of fibrogenic growth factors expression in peritoneum in a peritoneal dialysis rat model.
Chunming J; Miao Z; Cheng S; Nana T; Wei Z; Dongwei C; Yuan F
Ren Fail; 2011; 33(3):355-62. PubMed ID: 21401363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
